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Available online xxxxObjectives: To evaluate if a simplemethod for characterizing vaginal bleeding patterns in etonogestrel contracep-
tive implant users can predict subsequent patterns and bleeding-related discontinuation over the ﬁrst 2 years
of use.
Study Design: We reanalyzed phase 3 study bleeding data for non-breastfeeding participants from the United
States, Europe, Russia and Chile during the ﬁrst 2 years of implant use to characterize and correlate bleeding
patterns.We used 90-day reference periodswith period 1.1 starting at Day 29 and ending at Day 118.We dichot-
omized bleeding patterns as “favorable” (amenorrhea, infrequent bleeding and normal frequency bleedingwith-
out prolonged bleeding) or “unfavorable’ (prolonged and/or frequent bleeding) and tracked user groups based
on these bleeding patterns in reference period 1.1 through Year 1 and from Year 1 through Year 2, respectively.
Results: We evaluated data from 537 and 428 women with up to 1 and 2 years use, respectively. Of the 325
(60.5%) women with favorable bleeding in reference period 1.1, 275 (84.6%) reported favorable bleeding also
in reference period 2, 197 (60.6%) reported favorable bleeding throughout Year 1, and favorable bleeding in
75–85% of reference periods in Year 2. Among 212 (39.5%)womenwith unfavorable bleeding in reference period
1.1, 118 (55.7%) continuedwith unfavorable bleeding in reference period 2,while about 40%–50% reported favor-
able patterns in RP 2, 3 and/or 4. Initial favorable bleeding resulted in lower discontinuation rates than initial un-
favorable bleeding in years 1 (3.7% vs 12.7%, p≪.0001) and 2 (2.5% vs 16.5%, p≪.0001).
Conclusion: Implant users with favorable bleeding in the ﬁrst reference period are likely to continue with favor-
able bleeding over the next 2 years. Initial bleeding patterns predict overall continuation rates in years 1 and 2.
Implications Statement
When evaluating vaginal bleeding in any 90-day reference period over 2 years of etonogestrel implant use, ap-
proximately 80% ofwomenwith favorable and 40%with unfavorable bleeding patternswill have favorable bleed-
ing in the next reference periods. Theseﬁndings can facilitate counseling regarding bleeding forwomenusing the
etonogestrel implant.
Crown Copyright © 2019 Published by Elsevier Inc. All rights reserved.Keywords:
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D. Mansour et al. / Contraception 265100 (2019) 264-2681. IntroductionThe etonogestrel subdermal contraceptive implant, ﬁrstmarketed in
Europe in 1998 and the USA in 2006, has been used by more than 50
million womenworldwide (personal communication,Merck). Continu-
ation rates in clinical and observational studies are 80–90% at one and
65–75% at two years of use [1–3]. Acceptability and continuation rates
are also high in younger users [4–7]. Vaginal bleeding issues comprise
the main reason for implant removal, resulting in 13% of participants
discontinuing implantable contraception over 3 years follow-up in
USA and global phase III studies [1,5] and 16–19% in the ﬁrst year in ob-
servational studies [7–9].
Previous analyses have evaluated bleeding patterns in etonogestrel
implant users from phase 3 studies [8,10]. These analyses assessed
amenorrhea, infrequent, normal frequency, frequent, and prolonged
bleeding patterns over eight 90-day reference periods based on World
HealthOrganization (WHO) deﬁnitions (Table 1) [11].Womenwith fre-
quent or prolonged vaginal bleeding patterns more often discontinued
the implant before 2 years of use [10]. However, these analyses did
not track participants' bleeding patterns in later reference periods,
based on their initial bleeding patterns. The absence of such information
limits the use of existing published data for accurate patient counseling.
Additionally, the prior analyses included 214 women from Southeast
Asia (28.5% of the total population) who commonly report different
bleeding patterns and lower discontinuation rates than women from
other countries [10,12]. Discontinuation data from Europe/Chile and
the USA showed little differences in prior analyses [10]. Accordingly, we
have reanalyzed these data, excluding the subjects from Southeast Asia,
to evaluate how early bleeding experiences in non-Asian women corre-
late with bleeding patterns during the ﬁrst two years of implant use.2. Materials and methods
Details of the 12 phase 3 open-label studies for etonogestrel im-
plants have been previously published and include a total of 923
women [13]. Brieﬂy, investigators enrolled sexually active women, 18
to 40 years old, with regularmenstrual cycles and requesting contracep-
tion. Recruitment occurred in the late 1990s and early 2000s in 11 coun-
tries including the USA, Chile, Austria, Germany, Finland, Hungary, The
Netherlands, Russia, Singapore, Thailand and Malaysia. Appropriate in-
stitutional ethics committees approved the study for each site.Table 1
Deﬁnitions of favorable and unfavorable bleeding patterns
A. The characterization of bleeding patterns based on World Health Organization
recommended deﬁnitions [10,11]
•Amenorrhea: no bleeding/spotting days throughout a 90-day reference period
•Infrequent bleeding: 1–2 bleeding/spotting episodes in a 90-day reference
period
•Normal frequency: 3–5 bleeding/spotting episodes in a 90-day reference period
•Frequent bleeding: ≫5 bleeding/spotting episodes in a 90-day reference period
•Prolonged bleeding: any continuous bleeding/spotting episode lasting more
than 14 days in a 90-day reference period. This may overlap with any of the
other bleeding patterns except amenorrhea
B. Favorable and unfavorable bleeding patterns per reference period (as
deﬁned for this analysis)
Favorable bleeding patterns per reference period
•Amenorrhea
•Infrequent bleeding (1–2 episodes), without prolonged bleeding
•Normal frequency bleeding (3–5 episodes), without prolonged bleeding
Unfavorable bleeding patterns per reference period
•Frequent bleeding (6 or more episodes)
•Any prolonged bleeding
Reference period [each 90-day interval of use; for Reference Period 1,we excluded theﬁrst
28 days which shifted the ﬁrst reference period, Reference Period 1.1, to Days 29 through
Day 118with an overlap (Day 91 to Day 118) between Reference Period 1.1 and Reference
Period 2, (Day 91–180)].For this analysis, we extracted bleeding data from the study diary
databases, excluding women from Singapore (n=40), Thailand (n=
130) and Malaysia (n=69). We summarized bleeding patterns over
90-day reference periods, based on the WHO-recommended deﬁni-
tions and characterizations of bleeding patterns [11] (Table 1).
Using these deﬁnitions, we deﬁned the patterns as favorable (amen-
orrhea, infrequent bleeding and normal frequency bleeding with no
prolonged bleeding) or unfavorable (prolonged and/or frequent
bleeding) (Table 1) [10]. We tracked user groups based on these
bleeding patterns in reference period 1.1 through Year 1 and from
Year 1 through Year 2, respectively. None of the Phase III trials
allowed any hormonal treatments or other interventions for bleed-
ing complaints.
In most trials, implants were ﬁtted during Days 1–5 of partici-
pants' menstrual cycle, or the day after the last oral contraceptive
was taken in the pack, just before the expected withdrawal bleeding.
To minimize the effect of this bleeding on the analyses, we excluded
the ﬁrst 28 days of reference period 1, resulting in a shifted ﬁrst ref-
erence period, reference period 1.1, running from Day 29 to Day 118
with an overlap (Day 91 to Day 118) between Reference Period 1.1
and Reference Period 2. Bleeding data in this overlap period were in-
cluded both in Reference Period 1.1 and Reference Period 2 data. We
excluded study participants with missing bleeding diary data in Year
1 and/or Year 2 from our analyses. We excluded study participants
who discontinued implant use during the ﬁrst 118 days (for bleeding
or other reasons) because the analyses are based on the availability
of complete bleeding diary data for at least Reference Period 1.1.
We assessed implant discontinuation in each reference period due to
bleeding or other reasons. We compared bleeding patterns and discon-
tinuation rates for bleeding in Reference Periods 2, 3 and 4 in women
whohad favorable or unfavorable bleeding patterns in Reference Period
1.1. We also analyzed if favorable or unfavorable bleeding patterns in
Reference Period 2 or 3 predicted similar outcomes.
Our primary outcome was the correlation between favorable or un-
favorable bleeding patterns in Reference Period 1.1 and bleeding in the
subsequent reference periods in Year 1. Secondary outcomes included
the same correlations between Year 1 and Year 2 bleeding patterns, dis-
continuation due to bleeding and the impact of different deﬁnitions of
prolonged bleeding on bleeding patterns and implant discontinuation.
For the analyses of bleeding pattern correlation between the ﬁrst and
the second year, we deﬁned the overall ﬁrst year bleeding experience
as favorable (two or more reference periods with favorable bleeding
during Reference Periods 2, 3 and 4) or unfavorable (two or more refer-
ence periods with unfavorable bleeding during Reference Periods 2, 3
and 4). We then compared bleeding experiences and discontinuations
in Year 1 (Reference Periods 2, 3, 4) with Year 2 (Reference Periods 5,
6, 7, and 8). We conducted a sensitivity analysis for all outcomes
based on the deﬁnition of prolonged bleeding. The primary analysis
used the WHO deﬁnition of prolonged bleeding as any continuous
bleeding episode of≫14 days [11]; the sensitivity analyses evaluated
differences using≫7 or≫10-day cut-offs.
We used Fisher's Exact Test for comparing discontinuation in
women with favorable and unfavorable bleeding patterns in years
1 and 2, and a large sample test on Binomial proportion to test for
changes in the percentage of favorable bleedingwith a change of def-
inition of prolonged bleeding from 7 to 10 days and from 10 to 14
days within each reference period. We performed statistical analysis
using SAS (Carey, North Carolina) and considered a p≪.05 as
signiﬁcant.3. Results
Characteristics of the 537 evaluable study participants for these
analyses are listed in Table 2. Data concerning the lastmethod of contra-
ception used was available for 515 of the 537 women. We excluded 55
Table 2
Characteristics of Phase III etonogestrel implant bleeding analyses study participants
Characteristic Participants
n=537
Age (years) 27.5±5.6
Weight (kg) 61.7±9.2
Number of live births - n (%)
0 199 (37.1)
1 137 (25.5)
2 138 (25.7)
≥ 3 60 (11.2)
Missing 3 (0.6)
Number of pregnancies
0 128 (23.8)
1 119 (22.2)
2 150 (27.9)
≥ 3 140 (26.1)
Last contraceptive method
Oral (COC, POP) 161 (30.0)
IUD 57 (10.6)
Implant 2 (0.4)
Condom, Foam, Diaphragm, Spermicide 255 (47.5)
Other 25 (4.7)
Never used 15 (2.8)
Missing 22 (4.1)
Data are presented as n (%) or mean ± standard deviation.
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bleeding diary data, leaving 537 (90.7%) women in Year 1 and 428
(72.3%) women in Year 2 analyses (Table 3, online appendix Table 1).3.1. Correlation analyses Year 1
In Reference Period 1.1, 325 (60.5%) women reported a favorable
and 212 (39.5%) an unfavorable bleeding pattern (Fig. 1 and online ap-
pendix Table 2). Thirty-nine women (7.3%) discontinued treatment in
Year 1 due to bleeding and 68 (12.7%) did so for other reasons. Favorable
bleeding in Reference Period 1.1 generally correlates with a continua-
tion of favorable bleeding throughout Year 1 with favorable bleeding
patterns during Reference Periods 2, 3 and 4 reported by 275 (84.6%),
250 (80.4%) and 80 (80%), respectively. Overall, 197 (60.6%) women
with a favorable pattern in Reference Period 1.1 reported favorable
bleeding in all Reference Periods in Year 1. Few women (n=12, 3.7%)
with a favorable Reference Period 1.1. discontinued for bleeding reasons
in Year 1.
Women with an unfavorable bleeding pattern in Reference Period
1.1 reported less predictable future bleeding patterns in year one. AsTable 3
- Prolonged bleeding sensitivity analyses for bleeding pattern deﬁnitions and discontinuation a
Prolonged bleeding duration ≫14 days ≫10
Number and % of participants with favorable/unfavorable bleeding
Favorable
n (%)
Unfavorable
n (%)
Reference Period 1.1 537 325 (60.5%) 212 (39.5%) 537
Reference Period 2 508 354 (69.7%) 154 (30.3%) 508
Reference Period 3 463 342 (73.9%) 121 (26.1%) 463
Reference Period 4 430 320 (74.4%) 110 (25.6%) 430
Discontinuations for bleeding
In Year 1 12 (3.7%) 27 (12.7%)
In Year 2 8 (2.5%) 17 (8.0%)
Reference Period 1.1 (Days 29–118); Reference Period 2 (Days 91–180); Reference Period 3 (D
Favorable pattern: Amenorrhea, Infrequent bleeding without prolonged bleeding, normal frequ
Unfavorable pattern: Prolonged (≫14 days) and/or frequent bleeding.
Deﬁnition changes for the duration of bleeding that is called prolonged bleeding change the p
impact on the discontinuation rates per pattern of bleeding.demonstrated in Fig. 1A and online appendix Table 2, of the 212
women in this group, 79 (37.3%), 92 (46.7%) and 89 (51.1%) reported
a change to a favorable pattern in Reference Periods 2, 3 or 4, respec-
tively, and the proportion of womenwho reported continuing unfavor-
able bleeding rates declined over time from 55.7% (n=118) in
Reference Period 2 to 41.6% (n=81) in Reference Period 3 and 40.8%
(n=71) in Reference Period 4. Of the 79womenwho reported a change
from an unfavorable pattern in Reference Period 1.1 to a favorable pat-
tern in Reference Period 2; 51 (64.6%) also reported favorable bleeding
in Reference Period 3. In Year 1, signiﬁcantly more women (n=27,
12.7%) with an unfavorable pattern in Reference Period 1.1
discontinued due to bleeding compared towomenwith a favorable pat-
tern (n=12, 3.7% p≪.0001).
3.2. Correlation analyses Year 2
Of the 428 women in the Year 2 analyses, 325 (75.9%) reported an
overall favorable bleeding pattern in Year 1. We found similar correla-
tion patterns as in Year 1. As shown in Fig. 1B and online appendix
Table 2, favorable bleeding in Year 1 correlateswith favorable Reference
Periods 5, 6, 7 and/or 8 in 75–85% of women; 159 (48.9%) reported fa-
vorable bleeding throughout Year 2 with a low discontinuation rate
for bleeding (n=8, 2.5%). The trends reported in Year 1 in women
with unfavorable bleeding continued in Year 2 as well. Of the 103
women with unfavorable overall Year 1 bleeding patterns, 31–52% re-
ported a change to favorable bleeding over Reference Periods 5 to 8,
with rates of unfavorable bleeding declining from 52% to 38% of
women over Reference Periods 5 to 8. As in Year 1, discontinuation
rates for bleeding in this group were higher (n=17, 16.5%) than in
women with a favorable pattern (n=8, 2.5%; p≪.0001).
3.3. Correlations of bleeding patterns in preceding reference periods with
those in the next reference period
We observed that the bleeding pattern an individual woman experi-
ences in any reference period beyond Reference Period 1.1 generally
correlates with future bleeding. A favorable bleeding pattern reported
in any reference period is followed by reporting of continuation of fa-
vorable reference periods in 75% to 85% of women, unless one of the
prior reference periods is reported as unfavorable, in which case the
rate is 55–70% (see online appendix Table 3). In Year 2, womenwith re-
ported unfavorable bleeding in any reference period have similar likeli-
hood of a favorable or unfavorable pattern in the next reference period,
approximately 35–55%. Women have their implant removal more fre-
quently when they report the previous reference period as unfavorable
(see online appendix Table 3).mong women using an etonogestrel implant.
days ≫7 days
Favorable
n (%)
Unfavorable
n (%)
Favorable
n (%)
Unfavorable
n (%)
264 (49.2%) 273 (50.8%) 537 211 (39.3%) 326 (60.7%)
311 (61.2%) 197 (38.8%) 508 257 (50.6%) 251 (49.4%)
302 (65.2%) 161 (34.8%) 463 234 (50.5%) 229 (49.5%)
282 (65.6%) 148 (34.4%) 430 216 (50.2%) 214 (49.8%)
8 (3.0%) 31 (11.4%) 5 (2.4%) 34 (10.4%)
7 (2.7%) 18 (6.6%) 6 (2.8%) 19 (5.8%)
ays 181–270); Reference Period 4 (Days 271–360).
ency without prolonged bleeding.
roportions of women who have favorable or unfavorable bleeding patterns, but does not
267D. Mansour et al. / Contraception 100 (2019) 264-2683.4. Prolonged bleeding sensitivity analysis
Sensitivity analyses of changing the cut-offs for prolonged bleeding
from≫14 days (the WHO standard) to≫7 or≫10 days on favorable
and unfavorable bleeding patterns are reported in Table 3. As expected,
a less stringent deﬁnition of prolonged bleeding results in higher pro-
portions of reference periods categorized as unfavorable bleeding and
a change of deﬁnition of prolonged bleeding from ≫7 to ≫10 days or
≫10 to ≫14 days results in a highly signiﬁcant (p≪.0001) increase in
the proportion of favorable bleeding in each of the reference periods
over Year 1. However, the discontinuation rates in Year 1 in the
women having a favorable or an unfavorable pattern in Reference Pe-
riod 1.1 are not impacted by the changes in prolonged bleedingFig. 1. A) Bleeding patterns and discontinuation data in Reference Period 2, 3 and 4 in correl
patterns and discontinuation data in Year 2 (Reference Periods 5, 6, 7 and 8) in correlation witdeﬁnitions (≫7 to≫10 to≫14 days) (p-values 0.71and 0.6, respec-
tively). The same is true for Year 2 (p-values 0.96and 0.59, respectively).
4. Discussion
Our overall ﬁndings show that most women who have an initial fa-
vorable bleeding pattern continuewith this pattern for the next 2 years.
To aid counseling, women with a favorable bleeding pattern in any ref-
erence period can be informed that there is approximately an 80%
chance of this favorable pattern continuing to the next reference period.
Women with an initial unfavorable bleeding pattern are more likely to
have unpredictable bleeding in the future; they can be counseled that
there is an approximately 50% chance that their bleeding pattern willation with favorable and unfavorable bleeding patterns in reference period; B) Bleeding
h the bleeding pattern in Year 1 being deﬁned as favorable or unfavorable.
268 D. Mansour et al. / Contraception 100 (2019) 264-268improve over time. The likelihood of a favorable bleedingpattern during
Reference Periods 2, 3 and 4 are 37.3%, 46.7% and 51.1% respectively, and
of unfavorable patterns in Reference Period 2 is 55% and about 40% in
Reference Periods 3 and 4.
This is the ﬁrst report to demonstrate how predictive analyses of
progestin-only contraception bleeding data can facilitate counseling in
potential etonogestrel implant users. Previous publications have fo-
cused on data analyses of the number of bleeding days or patterns in
groups of users rather than individuals [10]. This current analysis evalu-
ates bleeding from the patient's perspective by identifying ‘favorable’
and ‘unfavorable’ patterns from previous publications and the discon-
tinuation rates associated with these patterns. Being sensitive to reli-
gious and cultural inﬂuences along with known differences in
bleeding patterns amongAsianwomenwhen using progestin-only con-
traception [12], we focused our attention on non-Asian women. A sub-
sequent analysis is planned to examine bleeding data in Asian women.
Prediction of future bleeding patterns in women with unfavorable
bleeding is more complex than in women with favorable bleeding.
About 40–50% of women with an unfavorable pattern in any one refer-
ence period are likely to havemore favorable bleeding in the next refer-
ence period but bleeding in future reference periods can vary. Attrition
bias may inﬂuence these ﬁndings as women with unfavorable patterns
are more likely to discontinue etonogestrel implant use.
The initial analysis of this dataset, reported in 2008, suggested that
the pattern experienced during the ﬁrst three months of implant use
was broadly predictive of future bleeding patterns for many women
[10]. Our re-analyses provide greater detail about the correlation be-
tween both favorable and unfavorable bleeding pattern rates across
two years and how individual patterns correlate with future bleeding.
We wanted to be sure that the WHO Belsey 1986 criteria [11], which
are more than 30 years old, did not lead us to misclassify women's pat-
terns as favorable when “prolonged” bleeding is classiﬁed as lasting for
more than 14 consecutive days. Women may be intolerant of prolonged
bleeding even at lesser durations. For this reason, we assessed
whether≫7 or≫10 days of prolonged bleeding may be better at
predicting outcomes. Importantly, shortening the deﬁnition of prolonged
bleeding did not result in any difference in discontinuation rates. How-
ever, the data from the Phase 3 trials is more than 15 years old and it is
possible thatmore contemporary datawould result in a different ﬁnding.
The dataset for this analysis has complete bleeding data for only
2 years, which limits our ability to attempt predictions for the third
year of use. Additionally, because the studies did not uniformly assess
weight and height, we cannot evaluate the relationship between BMI
and bleeding patterns. Most notably, the dataset was not set up to
allow analyses for continuation of amenorrhea based on individual
bleeding patterns. However, group analysis of amenorrhea over two
years with the etonogestrel implant done in 2008 shows that women
experience amenorrhea in 22% of the reference periods and this pattern
appeared to be acceptable, as indicated by high continuation rates in
such women [10]. Although we used diary data from Days 90–118 inboth Reference Periods 1.1 and 2, the overlap of this data does not ap-
pear to hide any changes in bleeding patterns as correlations between
Reference Period 1.1 and Reference Periods 2, 3 and 4 are largely the
same.
Future research could help answer important clinical questions, in-
cluding changes in bleeding patterns in women from different demo-
graphic and ethnic backgrounds and in women at the extremes of
bodyweight. In addition, exploring the change in patternswith replace-
ment of the etonogestrel implantwould help provide clearer counseling
messages.Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.contraception.2019.05.017.
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